Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for Macular Edema due to BRVO (BALATON)
NCT04740905Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of faricimab in Macular Edema Secondary to Branch Retinal Vein Occlusion, sponsored by Roche. Started Mar 2021; status: completed.
02
Drugs
faricimab
03
Conditions
Macular Edema Secondary to Branch Retinal Vein Occlusion
Beyond the preview
Go deeper on NCT04740905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740905.